Navigation Links
United States Joins Suits Against Scios and Johnson & Johnson
Date:2/19/2009

Pharmaceutical Companies Allegedly Marketed the Drug Natrecor for a Use Not Approved By the Food and Drug Administration

WASHINGTON, Feb. 19 /PRNewswire-USNewswire/ -- The United States has intervened in two whistleblower suits filed in the Northern District of California against the drug manufacturer Scios Inc. and its parent company, Johnson & Johnson Inc., alleging that the companies marketed the cardiac drug Natrecor for a use not approved by the Food and Drug Administration (FDA) and caused false and fraudulent claims to be submitted to the federal health care programs, the Justice Department announced today. Such an unapproved use is also known as an "off-label" use because it is not included in the drug's FDA approved product label.

Under the Food, Drug and Cosmetic Act, a company must specify the intended uses of a product in its new drug application to the FDA. Before approving a drug, the FDA must determine that the drug is safe and effective for the use proposed by the company. Once approved, the drug company may not market or promote the drug for off-label uses.

In August 2001, the FDA approved Natrecor for "the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea [shortness of breath] at rest or with minimal activity." The study upon which this approval was based involved hospitalized patients who had severe heart failure and who received infusions of Natrecor over an average 36-hour period. The government's investigation revealed that shortly after receiving this approval in 2001, Scios began an aggressive campaign to market Natrecor for scheduled, serial outpatient infusions for patients with less severe heart failure -- a use not included in the FDA-approved label. These patients were prescribed Natrecor infusions for less than six hours on a scheduled basis over an extended period of time.

Medicare doe
'/>"/>

SOURCE U.S. Department of Justice
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
2. United States continues to have highest level of health spending
3. United Medicorp, Inc.s Shareholders Approve All Proposals
4. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
5. Medical Services International Received Its First Order for Testing By Regulatory Agencies in the United States
6. Peoples United Financial CEO Has Surgery
7. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
8. More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States
9. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
10. Universal Health Care Coverage in the United States
11. Women Deliver Conference to Feature United Nations Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... have pinpointed a molecule that may trigger potentially life-threatening ... say this finding could offer a target for new ... Most asthma attacks (80 percent to 90 percent) are ... the British researchers. Most of these are rhinoviruses, which ... The researchers found that a specific molecule called IL-25 ...
(Date:10/2/2014)... Norton HealthDay Reporter WEDNESDAY, Oct. ... the roses -- literally -- may face an increased risk of ... a study of over 3,000 older Americans, researchers found those who ... were more than three times as likely to die in the ... In fact, anosmia -- the inability to distinguish odors -- ...
(Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
(Date:10/1/2014)... 1, 2014 Patients with increased inflammation, including ... greatly increased risk of depression. For example, a ... hepatitis C virus infection causes depression in approximately ... more commonly known as fish oil, have a ... risk of heart disease and reducing triglyceride levels. ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
Breaking Medicine News(10 mins):Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2
... poses heightened risk, but it,s talked about by only ... -- Even though people with rheumatoid arthritis (RA) may ... rarely discussed with their doctors, says a U.S. study ... , The researchers, led by Betsy Sleath, of the ...
... of Preventive Medicine and Partnership for Prevention ... Killer -, WASHINGTON, Feb. 11 The ... Prevention (Partnership) have joined,forces to change the way ... cost-effective disease prevention. The organizations,have targeted heart disease, ...
... PRINCETON, N.J., Feb. 11 New Jersey,s,hospitals would lose ... total,of $2.9 billion through 2013 if President Bush,s proposed ... by the New Jersey,Hospital Association., The cuts are ... last week. All told, the budget plan calls for ...
... HealthPartners first Minnesota health care organization to measure ... BLOOMINGTON, Minn., Feb. 11 HealthPartners,today released a ... different racial/ethnic backgrounds receiving certain types of,care in ... exist and,examples of improvements it is making to ...
... Women,s Cancer, Theme, Spotlights Four Decades of ... CHICAGO, Feb. 11 The Society of Gynecologic,Oncologists ... Women,s Cancer March,9-12 at the Tampa Convention Center ... more than 350 scientific presentations,lectures, workshops, symposium, surgical ...
... of UPMC have identified a key protein target that may ... to prevent and new therapies to treat pneumonia, the leading ... Kolls, MD, chief of the Division of Pediatric Pulmonary Medicine, ... the importance of a protein known as interleukin 22 (IL-22) ...
Cached Medicine News:Health News:Depression Rarely Discussed With RA Patients 2Health News:Nation's Leading Preventive Health Groups Seek to Save Lives by Transforming Americans' Approach to Health 2Health News:Nation's Leading Preventive Health Groups Seek to Save Lives by Transforming Americans' Approach to Health 3Health News:Nation's Leading Preventive Health Groups Seek to Save Lives by Transforming Americans' Approach to Health 4Health News:Bush Budget Cuts Total $2.9 Billion for N.J. Hospitals 2Health News:New Report Identifies Health Disparities and Reduction Strategies 2Health News:Society of Gynecologic Oncologists to Host 39th Annual Meeting on Women's Cancer 2Health News:Society of Gynecologic Oncologists to Host 39th Annual Meeting on Women's Cancer 3Health News:Children's Hospital scientists identify possible target for prevention and treatment of pneumonia 2
(Date:10/2/2014)... , Oct. 2, 2014  Isis Pharmaceuticals, Inc. ... webcast:What: , Webcast and conference call to provide ... clinical studies of ISIS-SMN Rx in infants ... will be presented on the morning (CEST) of ... Muscle Society in Berlin, GermanyWhen:Friday, October 10 at ...
(Date:10/2/2014)... Ireland , Oct. 2, 2014   West ... a global leader in innovative solutions for injectable drug ... manufacturing operations to include a new site in ... produce packaging components for insulin injector cartridges and other ... from pharmaceutical and biotech customers. Once operational, this new ...
(Date:10/2/2014)... 2014   Intarcia Therapeutics, Inc. today announced ... 3 clinical trials for ITCA 650 (exenatide, delivered continuously ... mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, double-blind ... safety of ITCA 650 in patients with type 2 ... be significantly superior to placebo for both 40 mcg ...
Breaking Medicine Technology:Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
... , BOSTON, Nov. 17 ... and information management solutions, today announced that it will showcase ... (IDNs) at the 2009 Radiological Society of North America (RSNA) ... IL. AMICAS will be in the North Hall in booth ...
... HistoRx today announced that the Company,s proprietary AQUA technology, ... was noted in a recent National Comprehensive Cancer ... testing in breast cancer as one of the "... promising ... PgR in breast cancer tissue." Experts from the country,s ...
Cached Medicine Technology:AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 2AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 3AQUA(R) Technology Recognized as 'Promising New Strategy' for Hormone Receptor Testing in Breast Cancer by NCCN Task Force 2
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: